<DOC>
	<DOCNO>NCT00102453</DOCNO>
	<brief_summary>In study , primary aim estimate magnitude variability strength change time may expect subject study treatment . This estimate effect allow u develop rigorous statistical plan future randomize study . The specific estimation technique apply use linear random effect model estimate average strength change 3-month lead-in period twelve-month treatment period , take account quantitative muscle test ( QMT ) measure subject . Accounting correlation repeat measure subject use random effect model yield unbiased estimate variability population average change strength . We use analysis pre- post-treatment data inform best estimate treatment effect . For example , difference QMT trend pre- post-treatment would provide straightforward measure efficacy .</brief_summary>
	<brief_title>Pentoxifylline Duchenne Muscular Dystrophy</brief_title>
	<detailed_description>Duchenne muscular dystrophy ( DMD ) progressive disease skeletal muscle cause absence dystrophin due genetic mutation x-linked dystrophin gene . The absence dystrophin result fragile muscle membrane permit abnormal permeability electrolyte , especially Ca ++ . The increase intracellular calcium trigger pathological cascade event ultimately result muscle necrosis fibrosis , impede normal muscle regeneration . The increase knowledge pathophysiology DMD open opportunity pharmacological treatment , purpose alter disease process revert muscle degeneration . This research study require Duchenne muscular dystrophy ( DMD ) subject 4 7 year old . We expect 5 child take part study Children 's Hospital 10 child participate hospital worldwide . There two ( 2 ) screen visit help decide whether able participate study . At second screen visit , blood test ( 13 tablespoon blood ) , EKG . Once study doctor decide eligibility study , subject come back month three month strength test . After three month , subject begin take pentoxifylline MRI ( test call MRI look inside muscle leg ) . This continue 12 month .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<criteria>1 . Male 2 . Age 4 7 year 3 . Ambulant independently . Subjects may use wheelchair occasionally , long distance 4 . Diagnosis DMD confirm least one following : Dystrophin immunofluorescence and/or immunoblot show complete dystrophin deficiency , clinical picture consistent typical DMD OR Gene deletion test positive ( miss one exon ) central rod domain ( exon 2560 ) dystrophin , read frame predict 'outofframe ' , clinical picture consistent typical DMD . Complete dystrophin gene sequence show alteration ( point mutation , duplication , mutation result stop codon mutation ) definitely associate DMD , typical clinical picture DMD . 5 . Positive family history DMD confirm one criterion list sibling maternal uncle , clinical picture typical DMD . 6 . Glucocorticosteroid na√Øve ( i.e . treat prednisone Deflazacort within 1 year onset study ) 7 . Has participate therapeutic research protocol within last 6 month . 8 . Evidence muscle weakness MRC score clinical functional evaluation 9 . Ability provide reproducible repeat QMT bicep score either right left arm within 15 % first assessment score . 1 . Symptomatic DMD carrier 2 . Use medication , nutritional supplement herb treatment DMD within last 3 month . 3 . Symptomatic cardiomyopathy ventricular arrhythmias 4 . History significant concomitant illness , impairment blood clot ability ( evidence increase PT/PTT bleeding time upper limit normal ( ULN ) ) , recent cerebral retinal hemorrhage , bleed diathesis , gastric ulcer , hypotension significant impairment renal hepatic function ( define serum creatinine GGT respectively , great 1.5 time normal upper limit age gender ) .</criteria>
	<gender>Male</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>7 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Duchenne</keyword>
	<keyword>Genetics</keyword>
</DOC>